In this study, we repurposed the LIVTAC XZ1606, originally developed for HCC, to treat liver fibrosis by inducing selective degradation of BRD4, a bromodomain-containing protein known to regulate fibrotic gene expression 25, 56. This evidence concerns the gene BRD4 and hepatocellular carcinoma.